drug · antibody
mirikizumab
Marketedupdated 6mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
indications
investigational
IBD (Crohn's + UC)
targets
Interleukin-23
all catalysts(5)
approval · 5
Oct 26, 2023
approval
$LLY1431.67-0.82%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Apr 29, 2024
approval
$LLY1431.67-0.82%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
$LLY1431.67-0.82%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
$LLY1431.67-0.82%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Oct 23, 2025
approval
$LLY1431.67-0.82%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Trials studying mirikizumab
- phase2A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- phase3A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- phase2A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- phase4INSIGHT-IBD Pragmatic Study
- phase2LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- phase4MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
- phase2A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- —VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that